Comparative Pharmacology
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus RAVOCAINE AND NOVOCAIN W LEVOPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON W XYLOCAINE versus RAVOCAINE AND NOVOCAIN W LEVOPHED.
DECADRON W/ XYLOCAINE vs RAVOCAINE AND NOVOCAIN W/ LEVOPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response. Lidocaine is a sodium channel blocker that stabilizes neuronal membranes, inhibiting nerve impulse initiation and conduction, producing local anesthesia.
Stabilizes neuronal membranes by blocking sodium channels, inhibiting initiation and conduction of nerve impulses. Levophed (norepinephrine) is an alpha-adrenergic agonist causing vasoconstriction.
Not a standard pre-mixed combination; individual components dosed separately. Dexamethasone: 0.5-9 mg/day oral/IV divided every 6-12h. Lidocaine: 1-5 mg/kg IV bolus (max 300 mg), then 1-4 mg/min IV infusion; or local infiltration up to 4.5 mg/kg (max 300 mg) with epinephrine.
Dental infiltration: 1-2 mL of 2% lidocaine with 1:100,000 epinephrine (max 7 mg/kg or 500 mg total). For NOVOCAIN (procaine) with LEVOPHED (levonordefrin): 1-2 mL of 2% procaine with 1:20,000 levonordefrin, max 600 mg procaine per session.
None Documented
None Documented
Dexamethasone: 3-4 hours (short-acting steroid). Lidocaine: 1.5-2 hours (prolonged in heart failure/hepatic disease).
Procaine: terminal elimination half-life approximately 40 seconds (rapid plasma hydrolysis); levonordefrin: elimination half-life about 5-10 minutes, clinically brief vasoconstrictor effect.
Dexamethasone: Renal (~65% as metabolites, <10% unchanged); Biliary/Fecal (<35%). Lidocaine: Hepatic metabolism to MEGX; Renal (<10% unchanged).
Renal excretion of unchanged drug and metabolites: procaine <2% unchanged, >80% as para-aminobenzoic acid (PABA) and diethylaminoethanol (DEAE); levonordefrin (Levophed) undergoes hepatic metabolism and renal excretion of metabolites, <5% unchanged.
Category C
Category C
Corticosteroid/Local Anesthetic Combination
Local Anesthetic Combination